Value through Innovation27 July 2016

Clinical Study Results

  • BI 695500 - Lymphoma, Non-Hodgkin
    Clinical Study Number 1301.6
    Study Indication Lymphoma, Non-Hodgkin
    Product BI 695500
    Generic Name BI 695500
    Lab Code
    Clinical Phase III
    Study Title

    A Phase III, randomized, double-blind, multi-center, multi-national trial to evaluate efficacy and safety of BI 695500 versus rituximab as a first-line immunotherapy treatment in patients with low tumor burden follicular lymphoma

    Study Document Trial statement 1301.6_DR english Trial synopsis 1301.6_DR english
  • BI 695500 - Arthritis, Rheumatoid
    Clinical Study Number 1301.1
    Study Indication Arthritis, Rheumatoid
    Product BI 695500
    Generic Name BI 695500
    Lab Code
    Clinical Phase I/III
    Study Title

    Efficacy, pharmacokinetics, and safety of BI 695500 versus rituximab in patients with moderately to severely active rheumatoid arthritis: a randomized, double-blind, parallel arm, multiple dose, active comparator trial

    Study Document Trial statement 1301.1 english Trial synopsis 1301.1_DS english
  • BI 695500 - Arthritis, Rheumatoid
    Clinical Study Number 1301.4
    Study Indication Arthritis, Rheumatoid
    Product BI 695500
    Generic Name BI 695500
    Lab Code
    Clinical Phase III
    Study Title

    Safety and Efficacy of BI 695500 in patients with moderately to severely active rheumatoid arthritis: an open-label extension trial

    Study Document Trial statement 1301.4 english Trial synopsis 1301.4_DS english
  • BI 695500 - Lymphoma, Follicular
    Clinical Study Number 1301.5
    Study Indication Lymphoma, Follicular
    Product BI 695500
    Generic Name BI 695500
    Lab Code BI 695500
    Clinical Phase I
    Study Title

    A randomized, double-blind, parallel-arm, Phase I study to evaluate pharmacokinetics and pharmacodynamics of BI 695500 vs. rituximab (MabThera®) induction immunotherapy as firstline treatment in patients with low tumor burden follicular lymphoma.

    Study Document Trial synopsis 1301.5 english
  • BI 695500 - Coronary Artery Disease , Lymphoma, Non-Hodgkin
    Clinical Study Number 1301.2
    Study Indication Coronary Artery Disease ; Lymphoma, Non-Hodgkin
    Product BI 695500
    Generic Name BI 695500
    Lab Code BI 695500
    Clinical Phase III
    Study Title

    A randomized, double-blind, multi-center, multi-national Phase III trial to compare efficacy and safety of BI 695500 plus chemotherapy versus rituximab plus chemotherapy in patients with untreated follicular non- Hodgkin’s lymphoma

    Study Document Trial statement 1301.2 english

Clinical Trial Registry and structured study results. Find here protocol information for all clinical study types.

European Trial Register of EU studies.